Company intelligence / Profile preview
Humacyte
North Carolina, United Stateshumacyte.gcs-web.com ↗
- Ownership
- Public · HUMA
- Development stage
- Commercial
01
Overview
FDA approved Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma in December 2024. The company's ATEV met primary endpoints in V007 Phase 3 clinical trial in arteriovenous access for hemodialysis. Over 430 patients have been treated with Human Acellular Vessels (HAVs) in clinical trials with no immunological rejections reported.
- Therapeutic areas
- EndocrinologyCardiovascularNephrology
- Modalities
- Bioengineered human tissuesAcellular Tissue Engineered Vessels (ATEV)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $99.9M
- Total revenue
- $406K
- Enterprise value
- $86.2M
Beyond the preview
Go deeper on Humacyte.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Humacyte.